Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

6 in Phase 3

Quick facts

Phase 3 pipeline

Asprin, Cilostazol · Cardiovascular
This combination of aspirin (antiplatelet) and cilostazol (phosphodiesterase-3 inhibitor) works synergistically to inhibit platelet aggregation and improve blood flow.
fiblast,gelatin sponge,fibrin glue
Non-PPI (Gefarnate) · Gastroenterology
Gefarnate is a mucoprotective agent that enhances gastric mucus production and strengthens the gastric mucosal barrier to protect against acid-induced damage.
tacrolimus + mycophenolate mofetil · Immunology / Transplantation
This combination suppresses T-cell activation and proliferation through calcineurin inhibition (tacrolimus) and inosine monophosphate dehydrogenase inhibition (mycophenolate mofetil) to prevent organ rejection.
tacrolimus + steroid · Immunology
Tacrolimus is an immunosuppressant that inhibits calcineurin, a protein phosphatase involved in the activation of T-lymphocytes, while steroids reduce inflammation and suppress the immune system.
UFT adjuvant chemotherapy · Oncology
UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

What is Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan's pipeline?

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan has 6 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Asprin, Cilostazol, fiblast,gelatin sponge,fibrin glue, Non-PPI (Gefarnate), tacrolimus + mycophenolate mofetil.

Sector hub: All tracked pharma companies